Ibogaine is dosed by body weight, typically somewhere between 8 and 15 milligrams per kilogram in published series. That convention conceals a problem which is arguably the most consequential and least discussed factor in ibogaine safety: two people of identical weight given an identical dose can end up with blood concentrations differing by more than tenfold, and the one with the higher concentration carries a proportionally greater cardiac risk.
The reason is genetic. A single liver enzyme does nearly all the work of clearing ibogaine, and the activity of that enzyme varies between individuals by inheritance. This entry sets out what is known about that variation, how it has been measured in patients, and what can and cannot be done to account for it.
The core fact
The enzyme is CYP2D6, part of the cytochrome P450 family that metabolises most drugs. Ibogaine is converted to noribogaine by removal of a methyl group, and work on human liver microsomes and recombinant enzymes established that CYP2D6 catalyses this reaction predominantly: the high-affinity CYP2D6 pathway accounted for more than 95 percent of intrinsic clearance, only recombinant CYP2D6 showed significant activity, and quinidine, a CYP2D6 inhibitor, blocked the reaction [1].
That study also examined a liver sample from an apparent poor metaboliser and found it retained only the slow, low-affinity alternative route [1]. A person whose CYP2D6 does not function therefore clears ibogaine by a backup pathway several times slower than the normal one.
What the enzyme does
CYP2D6 activity is not a simple present-or-absent trait. The gene exists in many variant forms, and people are commonly described by an activity score reflecting how many functional copies they carry. The resulting groups are usually called poor, intermediate, normal and ultrarapid metabolisers, and the clearance difference across that range is large.
The frequency of each group differs between populations. The review of ibogaine's cardiac pharmacology notes that CYP2D6 function is absent in roughly 5 to 10 percent of people of European ancestry [4], so a poor metaboliser is an uncommon but routine occurrence rather than a rarity. It also notes that CYP2D6 handles about 30 percent of currently used medicines [4], which means many drugs compete for or inhibit the same pathway.
One point of context matters for interpreting all of this. For most medicines, variable metabolism is managed by starting low and adjusting upward while watching the response. Ibogaine is given once, in a large dose, with no opportunity to titrate. The variation therefore translates directly into variation in peak exposure rather than being smoothed out over successive doses.
There is also a developmental and acquired layer on top of the genetic one. Liver function affects metabolism generally, so hepatic impairment slows clearance further, which is one reason published studies exclude participants with significant liver disease [5]. Age, concurrent illness and nutritional state all influence drug handling to some degree. Genotype is the largest single identified contributor and it is not the only one, which is part of why genotyping narrows uncertainty rather than removing it.
The patient data
The clearest measurement comes from a Dutch study of 14 adults with opioid use disorder, 12 on methadone and 2 on buprenorphine maintenance, 12 men and 2 women, median age 48. Participants were switched to oral morphine and given a single oral dose of ibogaine hydrochloride at 10 milligrams per kilogram. Plasma ibogaine, noribogaine and noribogaine glucuronide were sampled at 14 time points over 24 hours, CYP2D6 was genotyped, and the data were fitted with population pharmacokinetic modelling [2].
Ibogaine pharmacokinetics were highly variable and tied to CYP2D6 genotype, with the association reaching statistical significance, and the spread in clearance exceeded tenfold [2]. The study then correlated drug levels against clinical measures, using 386 electrocardiograms for QT interval, a standardised ataxia scale, and 54 withdrawal measurements.
That is a well-designed study and its sample is small. Fourteen patients establish the existence and rough magnitude of the effect; they do not characterise its full distribution. What they do establish is that the variation is not theoretical and not minor.
The companion report on the same cohort shows what that variation produced clinically. Maximum QT prolongation averaged 95 milliseconds with a range from 29 to 146, seven of the fourteen passed 500 milliseconds, and in six of the fourteen an interval above 450 milliseconds persisted beyond 24 hours. All fourteen developed severe transient ataxia and could not walk unaided [5]. A range of 29 to 146 milliseconds from a uniform dose per kilogram is the variation described above, expressed in the measure that matters.
Which compound carries the risk
The most clinically useful finding in that study concerns which of the two compounds drives the harmful effects. QT prolongation and ataxia tracked ibogaine concentrations rather than noribogaine concentrations [2].
This matters because it identifies which direction of metabolic variation is the dangerous one. A slow metaboliser retains more of the parent compound for longer, and the parent compound is the one associated with the cardiac effect. Fast conversion to noribogaine moves exposure toward the metabolite, which has a long half-life but was not what the QT changes tracked. Slow CYP2D6 activity is therefore the risk-increasing direction, which aligns with the enzyme-inhibition data.
If something here speaks to your situation, the next step is a five-minute provider match profile. We read it personally, take your case to vetted providers, and come back with the ones who say yes — or tell you honestly if ibogaine is not the answer.
Find a providerWhat happens when the enzyme is blocked
The interaction has been demonstrated prospectively. Twenty-one healthy volunteers were pretreated for six days with either placebo or paroxetine, a CYP2D6 inhibitor, then given a single 20 milligram oral dose of ibogaine, far below treatment doses, with sampling over 168 hours [3].
In the placebo group ibogaine was converted rapidly, noribogaine peaking at a median of 4 hours. With paroxetine, ibogaine remained detectable for 72 hours with an elimination half-life of 10.2 hours. Exposure to the combined active moiety was about twofold higher with paroxetine, and CYP2D6 phenotype correlated strongly with both ibogaine exposure and peak concentration [3].
The authors' recommendation is the most concrete dosing guidance anywhere in the ibogaine literature: it may be prudent to genotype, and to at least halve the intended dose in poor metabolisers [3]. That advice comes from a pharmacology group publishing in a clinical pharmacology journal, and it is specific, actionable and widely ignored.
Who is affected
Two groups carry elevated exposure for the same reason by different routes. The first is people who inherit reduced or absent CYP2D6 function, around 5 to 10 percent of those of European ancestry for complete absence [4], with intermediate metabolisers more common again.
The second is people taking a drug that inhibits the enzyme, which produces the same effect pharmacologically. Paroxetine was the inhibitor used experimentally; several other antidepressants, some antipsychotics and various other medicines inhibit CYP2D6 to differing degrees. Crucially for this population, methadone inhibits CYP2D6 and is likely to impair ibogaine metabolism [4].
That last point creates an unfortunate overlap. Many people seeking ibogaine for opioid dependence are on methadone, so the group most likely to present for treatment is also disproportionately likely to clear the drug slowly. This is one reason published protocols substitute a different opioid before dosing, as the St Kitts and Dutch series did [6] [5].
What can be done about it
Three measures follow from the evidence, and they differ in how often they are actually applied. Genotyping before dosing identifies poor metabolisers in advance and was recommended by the volunteer study's authors [3]. The St Kitts series genotyped CYP2D6 in a subset of its 191 participants [6], so the practice exists in research settings.
Dose reduction in known poor metabolisers follows directly, with at least halving suggested [3]. And a full medication review removes inhibitors before they compound the genetic variation, with sufficient washout for drugs that persist.
What none of these does is make exposure predictable. Genotype explains a large part of the variation but not all of it, and the Dutch study's modelling describes a population rather than forecasting an individual. The residual conclusion is that monitoring remains necessary because prediction is imperfect, and extended monitoring matters particularly for slow metabolisers, in whom both the drug and its cardiac effect persist longer.
A further limitation is that genotyping is not universally available or quick. Turnaround for a CYP2D6 panel takes days to weeks depending on the laboratory, which has to be arranged well before travel rather than on arrival. Genotype also predicts phenotype imperfectly, because an inhibiting drug can convert a genetically normal metaboliser into a functionally poor one, a phenomenon described as phenoconversion. A genotype result alongside an incomplete medication history can therefore be reassuring and wrong at the same time.
Why weight-based dosing misleads
Dosing by body weight gives an impression of precision that the pharmacology does not support. Weight affects the volume the drug distributes into, which is one determinant of concentration. Clearance rate is another, and for ibogaine clearance varies more than tenfold on genetic grounds alone [2]. A figure calculated to the milligram from a body weight is accurate about the amount administered and says little about the exposure that results.
Ibogaine is also lipophilic, so body composition rather than weight alone influences distribution, and the cardiac review notes storage in fat observed in rats [4]. Two people of equal weight and different composition are not equivalent, which adds a further source of variation on top of the enzymatic one.
The practical upshot is that a provider quoting a dose per kilogram has described their protocol, not the exposure a given person will experience. The questions that bear on exposure are whether CYP2D6 is genotyped or at least considered, whether interacting medicines have been identified and withdrawn with adequate washout, and how long monitoring continues after dosing.
Seen in this light, the variation is not an obscure pharmacological footnote but the mechanism by which an identical protocol produces a routine treatment for one person and a dangerous one for another. It also explains a pattern that otherwise looks puzzling: why severe cardiac events occur in people who were screened and found healthy, and why providers with apparently similar protocols report different experiences. If exposure varies more than tenfold on inherited grounds, then the dose on the chart is a poor predictor of what any individual heart is subjected to.
Frequently asked questions
Why does the same dose affect people so differently?
Mainly because CYP2D6 performs over 95 percent of ibogaine's clearance [1] and its activity is genetically variable, producing a more than tenfold spread in clearance among patients given the same dose per kilogram [2].
Should CYP2D6 be tested before treatment?
The authors of the inhibitor study suggested it may be prudent to genotype and to at least halve the dose in poor metabolisers [3]. One large case series genotyped a subset of participants [6].
Is being a slow or fast metaboliser the riskier position?
Slow. QT prolongation and ataxia tracked ibogaine rather than noribogaine concentrations [2], and slow metabolism keeps more of the parent compound present for longer.
Does genotyping make dosing safe?
It narrows the uncertainty rather than removing it. Genotype explains a large share of the variation but not all of it, an inhibiting drug can convert a normal metaboliser into a functionally poor one, and monitoring is still required because individual exposure cannot be forecast exactly [2] [3].
Which medicines matter most here?
CYP2D6 inhibitors, since blocking the enzyme roughly doubled active exposure in volunteers [3]. Methadone inhibits CYP2D6 and is likely to impair ibogaine metabolism [4], which is directly relevant to this population.
References
- Obach RS, Pablo J, Mash DC. 1998, Drug Metab Dispos 26(8):764-768. PMID 9698290. europepmc.org/article/MED/9698290
- Knuijver T, ter Heine R, Schellekens AFA, et al. 2024, J Psychopharmacol 38(5):481-488. doi:10.1177/02698811241237873. PMID 38519421. PMC11102648. europepmc.org/article/PMC/PMC11102648
- Glue P, Winter H, Garbe K, Jakobi H, Lyudin A, Lenagh-Glue Z, Hung CT. 2015, J Clin Pharmacol 55(6):680-687. doi:10.1002/jcph.471. PMID 25651476. doi.org/10.1002/jcph.471
- Koenig X, Hilber K. 2015, Molecules 20(2):2208-2228. doi:10.3390/molecules20022208. PMC4382526. mdpi.com/1420-3049/20/2/2208
- Knuijver T, Schellekens A, Belgers M, et al. 2022, Addiction 117(1). doi:10.1111/add.15448. PMC9292417. europepmc.org/article/PMC/PMC9292417
- Mash DC, Duque L, Page B, Allen-Ferdinand K. 2018, Front Pharmacol 9:529. frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2018.00529/full